Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 4, 2003, Pages 1220-1227

  Rogers, P David ^a,b,c   Barker, Katherine S ^a  

^a Nashville Clinical Education Center and Statewide   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; PYRROLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONFORMATIONAL TRANSITION; DRUG EFFECT; ENZYME ACTIVE SITE; FUNGUS ISOLATION; GENE EXPRESSION REGULATION; GENETIC REGULATION; GENETIC SUSCEPTIBILITY; GENOME; HUMAN; OPPORTUNISTIC INFECTION; POINT MUTATION; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, FUNGAL; GENES, MDR; GENOME, FUNGAL; HUMANS; OXIDATIVE STRESS;

EID: 0037378017     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.4.1220-1227.2003     Document Type: Article

References (56)

1. Bammert, G. F., and J. M. Fostel. 2000. Genome-wide expression patterns in Saccharomyces cerevisiae: comparison of drug treatments and genetic alterations affecting biosynthesis of ergosterol. Antimicrob. Agents Chemother. 44:1255-1265.
2. Black, S. M., and C. R. Wolf. 1991. The role of glutathione-dependent enzymes in drug resistance. Pharmacol. Ther. 51:139-154.
3. Buser, K., F. Joncourt, H. J. Altermatt, M. Bacchi, A. Oberli, and T. Cerny. 1997. Breast cancer: pretreatment drug resistance parameters (GSH-system, ATPase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics. Ann. Oncol. 8:335-341.
4. Cowen, L. E., A. Nantel, M. S. Whiteway, D. Y. Thomas, D. C. Tessier, L. M. Kohn, and J. B. Anderson. 2002. Population genomics of drug resistance in Candida albicans. Proc. Natl. Acad. Sci. USA 99:9284-9289.
5. De Backer, M. D., T. Ilyina, X. J. Ma, S. Vandoninck, W. H. Luyten, and H. Vanden Bossche. 2001. Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray. Antimicrob. Agents Chemother. 45:1660-1670.
6. de Micheli, M., J. Bille, C. Schueller, and D. Sanglard. 2002. A common drug-responsive element mediates the upregulation of the Candida albicans ABC transporters CDR1 and CDR2, two genes involved in antifungal drug resistance. Mol. Microbiol. 43:1197-1214.
7. DeRisi, J., B. van den Hazel, P. Marc, E. Balzi, P. Brown, C. Jacq, and A. Goffeau. 2000. Genome microarray analysis of transcriptional activation in multidrug resistance yeast mutants. FEBS Lett. 470:156-160.
8. Doroshow, J. H., S. Akman, F. F. Chu, and S. Esworthy. 1990. Role of the glutathione-glutathione peroxidase cycle in the cytotoxicity of the anticancer quinones. Pharmacol. Ther. 47:359-370.
9. Dowd, S. R., M. E. Bier, and J. L. Patton-Vogt. 2001. Turnover of phosphatidylcholine in Saccharomyces cerevisiae. The role of the CDP-choline pathway. J. Biol. Chem. 276:3756-3763.
10. Eisen, M. B., P. T. Spellman, P. O. Brown, and D. Botstein. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95:14863-14868.
11. Feigal, D. W., M. H. Katz, D. Greenspan, J. Westenhouse, W. Winkelstein, Jr., W. Lang, et al. 1991. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS 5:519-525.
12. Franz, R., M. Ruhnke, and J. Morschhäuser. 1999. Molecular aspects of fluconazole resistance development in Candida albicans. Mycoses 42:453-458.
13. Franz, R., S. L. Kelly, D. C. Lamb, D. E. Kelly, M. Ruhnke, and J. Morschhäuser. 1998. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother. 42:3065-3072.
14. Garay-Arroyo, A., and A. A. Covarrubias. 1999. Three genes whose expression is induced by stress in Saccharomyces cerevisiae. Yeast 15:879-892.
15. Hitchcock, C. A., K. J. Barrett-Bee, and N. J. Russell. 1986. The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans. J. Gen. Microbiol. 132:2421-2431.
16. Hitchcock, C. A., K. J. Barrett-Bee, and N. J. Russell. 1987. The lipid composition and permeability to azole of an azole- and polyene-resistant mutant of Candida albicans. J. Med. Vet. Mycol. 25:29-37.
17. Kan, V. L., A. Geber, and J. E. Bennett. 1996. Enhanced oxidative killing of azole-resistant Candida glabrata strains with ERG11 deletion. Antimicrob. Agents Chemother. 40:717-719.
18. Kaur, R., and A. K. Bachhawat. 1999. The yeast multidrug resistance pump, Pdr5p, confers reduced drug resistance in erg mutants of Saccharomyces cerevisiae. Microbiology 145:809-818.
19. Kelly, S. L., A. Arnoldi, and D. E. Kelly. 1993. Molecular genetic analysis of azole antifungal mode of action. Biochem. Soc. Trans. 21:1034-1038.
20. Kelly, S. L., D. C. Lamb, D. E. Kelly, N. J. Manning, J. Loeffler, H. Hebart, et al. 1997. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett. 400:80-82.
21. Klein, R. S., C. A. Harris, C. B. Small, B. Moll, M. Lesser, and G. H. Friedland. 1984. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N. Engl. J. Med. 311:354-358.
22. Klepser, M. E., D. Malone, R. E. Lewis, E. J. Ernst, and M. A. Pfaller. 2000. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob. Agents Chemother. 44:1917-1920.
23. Kobayashi, D., K. Kondo, N. Uehara, S. Otokozawa, N. Tsuji, A. Yagihashi, and N. Watanabe. 2002. Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect. Antimicrob. Agents Chemother. 46:3113-3117.
24. Kohli, A., Smriti, K. Mukhopadhyay, A. Rattan, and R. Prasad. 2002. In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry. Antimicrob. Agents Chemother. 46:1046-1052.
25. Kuipers, M. E., H. G. de Vries, M. C. Eikelboom, D. K. Meijer, and P. J. Swart. 1999. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrob. Agents Chemother. 43:2635-2641.
26. Lee, W. P., C. L. Lee, and H. C. Lin. 1996. Glutathione S-transferase and glutathione peroxidase are essential in the early stage of adriamycin resistance before P-glycoprotein overexpression in HOB1 lymphoma cells. Cancer Chemother. Pharmacol. 38:45-51.
27. Loffler, J., H. Einsele, H. Hebart, U. Schumacher, C. Hrastnik, and G. Daum. 2000. Phospholipid and sterol analysis of plasma membranes of azole-resistant Candida albicans strains. FEMS Microbiol. Lett. 185:59-63.
28. Lopez-Ribot, J. L., R. K. McAtee, L. N. Lee, W. R. Kirkpatrick, T. C. White, D. Sanglard, and T. F. Patterson. 1998. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 42:2932-2937.
29. Lyons, C. N., and T. C. White. 2000. Transcriptional analyses of antifungal drug resistance in Candida albicans. Antimicrob. Agents Chemother. 44:2296-2303.
30. Minn, Y., E. Brummer, and D. A. Stevens. 1997. Effect of iron on fluconazole activity against Candida albicans in presence of human serum or monocytederived macrophages. Mycopathologia 138:29-35.
31. Miralles, V. J., and R. Serrano. 1995. A genomic locus in Saccharomyces cerevisiae with four genes up-regulated by osmotic stress. Mol. Microbiol. 17:653-662.
32. Momose, Y., and H. Iwahashi. 2001. Bioassay of cadmium using a DNA microarray: genome-wide expression patterns of Saccharomyces cerevisiae response to cadmium. Environ. Toxicol. Chem. 20:2353-2360.
33. Morschhäuser, J. 2002. The genetic basis of fluconazole resistance development in Candida albicans. Biochim. Biophys. Acta 1587:240-248.
34. Nawrocki, A., S. J. Fey, A. Goffeau, P. Roepstorff, and P. M. Larsen. 2001. The effects of transcription regulating genes PDR1, pdr1-3 and PDR3 in pleiotropic drug resistance. Proteomics 1:1022-1032.
35. Niino, Y. S., S. Chakraborty, B. J. Brown, and V. Massey. 1995. A new old yellow enzyme of Saccharomyces cerevisiae. J. Biol. Chem. 270:1983-1991.
36. Nolte, F. S., T. Parkinson, D. J. Falconer, S. Dix, J. Williams, C. Gilmore, et al. 1997. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob. Agents Chemother. 41:196-199.
37. Perea, S., J. L. Lopez-Ribot, W. R. Kirkpatrick, R. K. McAtee, R. A. Santillan, M. Martinez, et al. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 45:2676-2684.
38. Pereira, M. D., E. C. Eleutherio, and A. D. Panek. 2001. Acquisition of tolerance against oxidative damage in Saccharomyces cerevisiae. BMC Microbiol. 1:11.
39. Pfaller, M. A., J. Rhine-Chalberg, S. W. Redding, J. Smith, G. Farinacci, A. W. Fothergill, and M. G. Rinaldi. 1994. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J. Clin. Microbiol. 32:59-64.
40. Redding, S., J. Smith, G. Farinacci, M. Rinaldi, A. Fothergill, J. RhineChalberg, and M. Pfaller. 1994. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin. Infect. Dis. 18:240-242.
41. Rogers, P. D., and K. S. Barker. 2002. Evaluation of differential gene expression in fluconazole-susceptible and -resistant isolates of Candida albicans using cDNA microarray analysis. Antimicrob. Agents Chemother. 46:3412-3417.
42. Ruhnke, M., A. Eigler, I. Tennagen, B. Geiseler, E. Engelmann, and M. Trautmann. 1994. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J. Clin. Microbiol. 32:2092-2098.
43. Sanglard, D. 2002. Resistance of human fungal pathogens to antifungal drugs. Curr. Opin. Microbiol. 5:379-385.
44. Sanglard, D., F. Ischer, L. Koymans, and J. Bille. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42:241-253.
45. Sanglard, D., K. Kuchler, F. Ischer, J. L. Pagani, M. Monod, and J. Bille. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
46. Shimizu, M., W. Li, P. A. Covitz, M. Hara, H. Shindo, and A. P. Mitchell. 1998. Genomic footprinting of the yeast zinc finger protein Rme1p and its roles in repression of the meiotic activator IME1. Nucleic Acids Res. 26:2329-2336.
47. Soustre, I., Y. Letourneux, and F. Karst. 1996. Characterization of the Saccharomyces cerevisiae RTA1 gene involved in 7-aminocholesterol resistance. Curr. Genet. 30:121-125.
48. Sreenivas, A., M. J. Villa-Garcia, S. A. Henry, and G. M. Carman. 2001. Phosphorylation of the yeast phospholipid synthesis regulatory protein Opi1p by protein kinase C. J. Biol. Chem. 276:29915-29923.
49. Sturtz, L. A., K. Diekert, L. T. Jensen, R. Lill, and V. C. Culotta. 2001. A fraction of yeast Cu,Zn-superoxide dismutase and its metallochaperone, CCS, localize to the intermembrane space of mitochondria. A physiological role for SOD1 in guarding against mitochondrial oxidative damage. J. Biol. Chem. 276:38084-38089.
50. Toke, D. A., W. L. Bennett, J. Oshiro, W. I. Wu, D. R. Voelker, and G. M. Carman. 1998. Isolation and characterization of the Saccharomyces cerevisiae LPP1 gene encoding a Mg2+-independent phosphatidate phosphatase. J. Biol. Chem. 273:14331-14338.
51. Viarengo, A., B. Burlando, N. Ceratto, and I. Panfoli. 2000. Antioxidant role of metallothioneins: a comparative overview. Cell. Mol. Biol. 46:407-417.
52. Wakabayashi, H., T. Okutomi, S. Abe, H. Hayasawa, M. Tomita, and H. Yamaguchi. 1998. Enhanced anti-Candida activity of neutrophils and azole antifungal agents in the presence of lactoferrin-related compounds. Adv. Exp. Med. Biol. 443:229-237.
53. White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.
54. White, T. C. 1997. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans. Antimicrob. Agents Chemother. 41:1488-1494.
55. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
56. Wirsching, S., S. Michel, G. Kohler, and J. Morschhäuser. 2000. Activation of the multiple drug resistance gene MDR1 in fluconazole-resistant, clinical Candida albicans strains is caused by mutations in a trans-regulatory factor. J. Bacteriol. 182:400-404.